By Louis Garguilo, Chief Editor, Outsourced Pharma
Can it be that today, when we expect increasing demand for CDMO services, biopharmaceutical companies have decided to outsource less of their commercial production needs than in the past? Some new data provided exclusively to Outsourced Pharma by PharmSource, an organization of GlobalData Plc., seems to suggest so. But if so, why that apparent trend reversal?
By Bill Bolding and Ajeya Shekar, Provident Healthcare Partners
The CDMO industry has benefitted from Big Pharma’s divestment of in-house development and manufacturing capabilities in this current economic cycle. The rise of competition from new CDMO players and consolidation within the pharmaceutical sponsor space, however, has led to a crowded market and, in many cases, a commoditized service base.
Bias can take many forms and is often not easily recognized by an investigator. Sherlock Holmes was keenly aware of bias's potential impacts. Applying more of Holmes’s famous observations and investigative principles can uncover hidden bias and greatly increase an investigator’s chance of finding that elusive definitive root cause.